PTC Therapeutics
PTCT
215 hedge funds and large institutions have $4.46B invested in PTC Therapeutics in 2020 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 66 increasing their positions, 82 reducing their positions, and 21 closing their positions.
4,153% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $256K
90% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 21
34% more capital invested
Capital invested by funds: $3.34B → $4.46B (+$1.13B)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
9% more funds holding
Funds holding: 197 → 215 (+18)
1.63% more ownership
Funds ownership: 105.61% → 107.24% (+1.6%)
20% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$57.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22M |
| 3 |
Goldman Sachs
New York
|
+$19M |
| 4 |
BlackRock
New York
|
+$16.8M |
| 5 |
RI
RTW Investments
New York
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11.5M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$10.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$10.1M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$8.87M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.77M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
Rockefeller Capital Management
New York
| – | -$130K | -2,787 | Closed |
|
|
PCM
227
Prelude Capital Management
New York
| – | -$61K | -1,300 | Closed |
|
|
FFA
228
Founders Financial Alliance
Raleigh,
North Carolina
| – | -$28K | -600 | Closed |
|
|
PI
229
PEAK6 Investments
Chicago,
Illinois
| – | -$21K | -447 | Closed |
|
|
CIA
230
CSat Investment Advisory
Detroit,
Michigan
| – | -$9K | -193 | Closed |
|
|
SL
231
Savior LLC
Wellesley Hills,
Massachusetts
| – | -$5K | -100 | Closed |
|
|
ASN
232
Advisory Services Network
Atlanta,
Georgia
| – | -$4.07K | -69 | Closed |
|
|
GT
233
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$1K | -40 | Closed |
|
|
CWC
234
Carolinas Wealth Consulting
Charlotte,
North Carolina
| – | -$1K | -15 | Closed |
|
|
AP
235
Arlington Partners
Birmingham,
Alabama
| – | +$177 | +3 | New |
|
PTCT Hedge Fund Activity: Q4 2020 in Review
215 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2020, worth a combined $4.46B — up 34% from $3.34B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new PTCT positions and 21 closed out — a net gain of 19 holders — while 66 added to existing stakes and 82 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $57.6M. The largest seller was Assenagon Asset Management, cutting an estimated $11.5M.
- 215 institutional investors held PTC Therapeutics (PTCT) as of Q4 2020, up from 197 in Q3 2020.
- Funds reported $4.46B of PTC Therapeutics stock for Q4 2020, up 34% quarter-over-quarter.
- 40 funds opened new PTC Therapeutics positions in Q4 2020 and 21 closed out, a net change of +19 holders.
- The largest PTC Therapeutics buyer in Q4 2020 was Janus Henderson Group, an estimated $57.6M added.
- The largest PTC Therapeutics seller in Q4 2020 was Assenagon Asset Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q4 2020.